title: Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.
abstract: We examined the levels of platelet vascular endothelial growth factor (VEGF(PLT)) and serum level of transforming growth factor beta 1 (TGF-β1) in non-small cell lung cancer (NSCLC) patients before and after chemotherapy to assess their clinical value as biomarkers. A total of 115 subjects were recruited at the First Hospital of Qinhuangdao between July 2012 and October 2013, including 65 NSCLC patients receiving chemotherapy (NSCLC group) and 50 healthy controls (control group). All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. VEGF(PLT) and serum TGF-β1 levels were measured before and after chemotherapy using enzyme-linked immunosorbent assay (ELISA). Platelet count was obtained using the Abbott CD-1600 auto blood analyzer. NSCLC group was categorized into complete response (CR) plus partial response (PR) group and stable disease (SD) plus progressive disease (PD) group based on the results of CT scans obtained 1 week after chemotherapy. Our results revealed that VEGF(PLT) and serum TGF-β1 levels were significantly higher in NSCLC group before chemotherapy, compared to the control group (VEGF(PLT), 0.813 ± 0.072 vs. 0.547 ± 0.024; t = 26.48; P < 0.001 and TGF-β1, 46.00 ± 4.47 vs. 16.43 ± 2.12; t = 44.87; P < 0.001). Importantly, VEGF(PLT) and serum TGF-β1 levels decreased significantly after chemotherapy in CR + PR group in comparison with before chemotherapy (VEGF(PLT), 0.453 ± 0.078 vs. 0.814 ± 0.127; t = 15.51; P < 0.001 and TGF-β1, 20.17 ± 2.43 vs. 42.13 ± 4.54; t = 27.31; P < 0.001). By contrast, VEGF(PLT) and serum TGF-β1 levels were markedly higher after chemotherapy in the SD + PD group in comparison with before chemotherapy (VEGF(PLT), 0.816 ± 0.043 vs. 1.065 ± 0.016; t = 22.38; P < 0.001 and TGF-β1, 41.80 ± 5.46 vs. 45.83 ± 4.62; t = 2.32; P = 0. 03). Our results show that NSCLC patients exhibit high VEGF(PLT) and serum TGF-β1 levels, and VEGF(PLT) and TGF-β1 levels correlate with chemotherapy response to GP regimen. Therefore, VEGF(PLT) and serum TGF-β1 levels are valuable biomarkers in clinical monitoring of NSCLC patients.
authors.affiliation: Department of Oncology, the First Hospital of Qinhuangdao City, Wenhua Road No. 258, Haigang, Qinhuangdao, 066000, People's Republic of China.
authors.forename: Bao-Hong
authors.initials: BH
authors.lastname: Fu
authors.forename: Zhan-Zhao
authors.initials: ZZ
authors.lastname: Fu
authors.forename: Wei
authors.initials: W
authors.lastname: Meng
authors.forename: Tao
authors.initials: T
authors.lastname: Gu
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Sun
authors.forename: Zhi
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001792:Blood Platelets / Q000378:metabolism / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000097:blood*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis / Q000097:blood*; D000093542:Gemcitabine
chemical_list: D016212:Transforming Growth Factor beta; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
references.citation: Oncol Rep. 2012 Apr;27(4):1065-71
references.pmid: 22138668
references.citation: Cytokine. 2011 Mar;53(3):370-5
references.pmid: 21208810
references.citation: Eur J Surg Oncol. 2014 Mar;40(3):311-7
references.pmid: 24332948
references.citation: PLoS One. 2013 Oct 02;8(10):e76346
references.pmid: 24098479
references.citation: Platelets. 2010;21(2):85-93
references.pmid: 20063989
references.citation: Biol Pharm Bull. 2011;34(12):1773
references.pmid: 22130228
references.citation: Cytokine. 2010 Sep;51(3):245-8
references.pmid: 20599393
references.citation: PLoS One. 2013 Oct 11;8(10):e77024
references.pmid: 24146953
references.citation: Med Oncol. 2014 Oct;31(10):194
references.pmid: 25154761
references.citation: Jpn J Clin Oncol. 2010 Dec;40(12):1147-53
references.pmid: 20647232
references.citation: Cytokine Growth Factor Rev. 2010 Feb;21(1):49-59
references.pmid: 20018551
references.citation: Ann Oncol. 2012 Jun;23 (6):1549-55
references.pmid: 22056973
references.citation: Pol Merkur Lekarski. 2014 May;36(215):298-301
references.pmid: 24964504
references.citation: PLoS One. 2013 Nov 19;8(11):e76372
references.pmid: 24260099
references.citation: Haematologica. 2011 Sep;96(9):1302-9
references.pmid: 21606166
references.citation: Nature. 2010 May 27;465(7297):483-6
references.pmid: 20445537
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3749-54
references.pmid: 21321221
references.citation: Oncogene. 2008 Oct 6;27(45):5913-9
references.pmid: 18836472
references.citation: PLoS One. 2011 Jan 13;6(1):e16068
references.pmid: 21249152
references.citation: Genes Cancer. 2011 Dec;2(12):1097-105
references.pmid: 22866201
references.citation: Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):165-74
references.pmid: 23283519
references.citation: Clin Chest Med. 2011 Dec;32(4):605-44
references.pmid: 22054876
references.citation: Carcinogenesis. 2008 Nov;29(11):2227-35
references.pmid: 18725385
references.citation: Tumour Biol. 2014 May;35(5):4785-9
references.pmid: 24557540
references.citation: Nat Rev Immunol. 2011 Apr;11(4):264-74
references.pmid: 21436837
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Mayo Clin Proc. 2008 May;83(5):584-94
references.pmid: 18452692
references.citation: J Mol Cell Cardiol. 2011 Oct;51(4):600-6
references.pmid: 21059352
references.citation: Ann Surg Oncol. 2015 Feb;22(2):630-5
references.pmid: 25145502
references.citation: Circ Res. 2013 May 24;112(11):1506-19
references.pmid: 23704217
references.citation: J Appl Clin Med Phys. 2012 Sep 01;14(1):4110
references.pmid: 23318374
references.citation: Am J Respir Cell Mol Biol. 2011 Feb;44(2):127-33
references.pmid: 20525803
references.citation: DNA Cell Biol. 2014 Jul;33(7):426-37
references.pmid: 24628278
references.citation: Neurosci Lett. 2013 Aug 29;550:60-3
references.pmid: 23827227
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16618-23
references.pmid: 22996328
references.citation: Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1402-7
references.pmid: 18234432
references.citation: Cancer Invest. 2011 Mar;29(3):202-7
references.pmid: 21280981
references.citation: Cancer Epidemiol. 2013 Oct;37(5):750-3
references.pmid: 23727122
references.citation: Lancet. 2009 Aug 1;374(9687):379-86
references.pmid: 19632716
references.citation: Int J Health Geogr. 2011 Jan 25;10:10
references.pmid: 21266041
references.citation: N Engl J Med. 2011 Aug 4;365(5):395-409
references.pmid: 21714641
references.citation: Cancer Res Treat. 2013 Dec;45(4):325-33
references.pmid: 24454005
references.citation: Nan Fang Yi Ke Da Xue Xue Bao. 2011 Apr;31(4):619-23
references.pmid: 21515455
references.citation: Angiogenesis. 2012 Jun;15(2):265-73
references.pmid: 22402885
references.citation: Lancet Oncol. 2011 Feb;12(2):175-80
references.pmid: 21277552